Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Rare Tumour × pembrolizumab × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 373 Melanoma 242 Squamous Cell Carcinoma of Head and Neck 186 Parkinson Disease 4, Autosomal Dominant Lewy Body 157 Neoplasms 146 Breast Neoplasms 135 Neoplasm Metastasis 128 Triple Negative Breast Neoplasms 126 Colorectal Neoplasms 119 Lung Neoplasms 117 Carcinoma, Renal Cell 108 Head and Neck Neoplasms 96 Ovarian Neoplasms 84 Stomach Neoplasms 80 Carcinoma, Transitional Cell 70 Pancreatic Neoplasms 69 Urinary Bladder Neoplasms 67 Carcinoma, Hepatocellular 58 Endometrial Neoplasms 57 Uterine Cervical Neoplasms 52 Esophageal Neoplasms 48 Recurrence 46 Prostatic Neoplasms 42 Carcinoma 36 Glioblastoma 35 Carcinoma, Squamous Cell 34 Sarcoma 32 Lymphoma 32 Hodgkin Disease 31 Small Cell Lung Carcinoma 30

Interventions

toripalimab 1 tislelizumab 1 sintilimab 1 pyrotinib 1 pembrolizumab 1 pamiparib 1 palbociclib 1 osimertinib 1 neratinib 1 erdafitinib 1 envafolimab 1 entrectinib 1 durvalumab 1 camrelizumab 1 atezolizumab 1 alectinib 1 Vinorelbine 1 Vemurafenib 1 Teniposide 1 Nivolumab 1 Irinotecan 1 Imatinib Mesylate 1 Gemcitabine 1 Fluorouracil 1 Epirubicin 1 Cisplatin 1 Albumin-Bound Paclitaxel 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06692491 2024-11-18

SPRING

Peking University Shenzhen Hospital

Phase 2 Not yet recruiting

Rare Tumour

Data powered by HemOnc (CC BY 4.0) Colophon ⚡